Fig 2: RCC2 expression levels are upregulated in the urogenital male reproductive system and were associated with poor clinical prognosis. (A) Scatter plot of RCC2 in prostate cancer and normal tissues. (B) Scatter plot of RCC2 in bladder urothelial carcinoma and normal tissues. (C) Scatter plot of RCC2 in renal clear cell carcinoma and normal tissues. RCC2 in (D) patients with prostate cancer, (E) patients with bladder urothelial carcinoma and (F) patients with kidney clear cell carcinoma data was analyzed by Kaplan-Meier analysis (***P<0.001). RCC2, regulator of chromosome condensation 2; N, normal; T, tumor.

Fig 3: High expression levels of RCC2 in the head and neck squamous cell carcinoma and lung adenocarcinoma. Scatter plot of RCC2 in (A) head and neck squamous cell carcinoma and normal tissues and (B) lung adenocarcinoma and normal tissues. Kaplan-Meier analysis of RCC2 in (C) head and neck squamous cell carcinoma patients. (D) Kaplan-Meier analysis of RCC2 in lung adenocarcinoma patients (***P<0.001). RCC2, regulator of chromosome condensation 2; N, normal; T, tumor.

Fig 4: RCC2 is highly expressed in CRC tissues and associates with HMGA2 to promote malignant CRC progression. (A) Representative immunohistochemical staining of RCC2 in CRC tissues and correspondence normal tissues (magnifications x25 and inset, x100). (B) Immunohistochemical staining score of RCC2 in 36 paired CRC tissues. (C) Western blot analysis of RCC2 and HMGA2 in CRC cell lines. (D) Immunoprecipitation of the Myc-HMGA2 by an anti-FLAG antibody in 293 cells transfected with pcDNA3.1-FLAG-RCC2 and/or pcDNA3.1-Myc-HMGA2 as indicated. (E) Endogenous RCC2 was coprecipitated with endogenous HMGA2. (F) CCK8 analysis was conducted to detect the cells proliferation. (G) Colony formation assays were carried out to explore the effect of RCC2 and HMGA2 on the proliferation of HCT116 cells. Left panel: representative images, right panel: quantification analysis. (H) Transwell migration and invasion assays were performed (left panel) and calculation of the rate of migration/invasion in corresponding HCT116 cells (right panel) (red scale bar, 100 µm). (I) Apoptosis was detected by 7AAD/Annexin-V labeling, quantitation of data is shown. (J) FN1 and (K) IL11 mRNA expressions were measured by reverse transcription-quantitative PCR. Data are shown as the mean ± standard deviation of triplicate independent sets of experiments (***P<0.001, ****P<0.0001, ns, non-significant). RCC2, regulator of chromosome condensation 2; CRC, colorectal cancer; HMGA2, high mobility group A2; FN1, fibronectin 1.

Fig 5: High expression levels of RCC2 in endometrial cancer and sarcoma are correlated with worse clinical outcomes. Scatter plot of RCC2 in (A) endometrial cancer and normal tissues and (B) sarcoma and normal tissues. Kaplan-Meier analysis of RCC2 in patients with (C) endometrial cancer and (D) sarcoma (*P<0.05, ***P<0.001). RCC2, regulator of chromosome condensation 2; N, normal; T, tumor.